<DOC>
	<DOCNO>NCT01226407</DOCNO>
	<brief_summary>Open label , single dose phase I study . The primary objective : To determine maximum tolerate dose Single dose The secondary objective : evaluate toxicity administration determine desirable dose amount phase II evaluate tumor response progressive solid cancer patient evaluate pharmacokinetic/ pharmacodynamic profile .</brief_summary>
	<brief_title>Examine Maximum Tolerated Dose Pharmacokinetic Pharmacodynamic Profile</brief_title>
	<detailed_description>1 . Number Subjects : 28~36 , dose escalation ( 2~6 subject step ) 2 . Adverse Events cod preferred therm body system use CTCAE</detailed_description>
	<criteria>20 year old 69 year old diagnose progressive solid cancer In spite standard chemotherapy , efficacy treatment life extension expect . Evaluated 01 ECOG Expected life duration within 3 month Major surgery except tumorremoval surgery receive within 2 week screen . history CNS metasis hypersensitivy study drug pregancy lactate administer HDAC inhibitor within 4 week screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Solid Tumour</keyword>
</DOC>